717-P: Real-World, Patient-Reported Data on Training and Use of 670G Hybrid Closed-Loop (HCL) among Children and Adults with Type 1 Diabetes (T1D)

This report describes patient-reported data from persons with T1D initiating use of the Medtronic MiniMed 670G HCL insulin delivery system (670G) for clinical care. Questionnaires were completed in clinic before starting the system, and then follow up surveys were emailed at 6 weeks, 6 months and 12 months from the time of enrollment. Participants who completed the 6 week survey (n=97) had a mean HbA1c of 8.2%, T1D duration of 19 yrs, median age of 37 yrs, with 57% being female, 88% non-Hispanic white. Most were on pump therapy at baseline with 87% using a sensor. Nearly all who completed the training questionnaire agreed/strongly agreed that he/she received adequate training on the majority of the 670G components. Alarms were described as somewhat to very bothersome during the day by nearly half of participants/parents and more than half had issues with sleep interruption at night (Table). Close to half (~40%) noted frequent exits from Auto Mode were somewhat to very bothersome. In this real-world assessment of 670G use, while many were satisfied by device training, issues with the system were prevalent amongst those who persisted with device use. With this first in-class device, this study highlights that methods to minimize burdens of HCL use, such as the number of alarms and frequent exits from automation, will be essential for alternate and next generation systems. Disclosure C. Bauza: None. S. Dubose: None. A. Verdejo: None. R. Beck: Consultant; Self; Bigfoot Biomedical, Inc., Diasome Pharmaceuticals, Inc., Insulet Corporation, Lilly Diabetes, vTv Therapeutics, Research Support; Self; Beta Bionics, Inc., Dexcom, Inc., Medtronic, Novo Nordisk, Tandem Diabetes Care. R. M. Bergenstal: Advisory Panel; Self; Abbott Diabetes, Eli Lilly and Company, Novo Nordisk, Onduo LLC., Roche , Sanofi, United Healthcare , Consultant; Self; Abbott Diabetes, Ascensia , Dexcom, Inc., Eli Lilly and Company, Hygieia, Johnson & Johnson, Medtronic, Novo Nordisk, Onduo LLC., Roche, Sanofi, United Healthcare, Other Relationship; Self; HealthPartners Institute, Research Support; Self; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Helmsley Charitable Trust, Hygieia, Johnson & Johnson, Medtronic, NIDDK, Novo Nordisk, Onduo LLC., Roche, Sanofi, United Healthcare. J. Sherr: Advisory Panel; Self; Cecelia Health, Insulet Corporation, Medtronic, Consultant; Self; Insulet Corporation, Lexicon Pharmaceuticals, Inc., Lilly Diabetes, Medtronic, Research Support; Self; Dexcom, Inc., Insulet Corporation, Medtronic, Speaker’s Bureau; Self; Lilly Diabetes. Funding The Leona M. and Harry B. Helmsley Charitable Trust